View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Feb. 28, 2014	Apr. 08, 2014
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Feb. 28, 2014
Entity Registrant Name	ORAMED PHARMACEUTICALS INC.
Entity Central Index Key	0001176309
Current Fiscal Year End Date	--08-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2014
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		9,942,589

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Feb. 28, 2014	Aug. 31, 2013
CURRENT ASSETS:
Cash and cash equivalents	$ 3,252,911	$ 2,272,228
Short term deposits	18,633,526	5,246,627
Marketable securities	1,464,100	956,376
Restricted cash	16,000	16,000
Prepaid expenses and other current assets	245,596	90,103
Related parties	1,712	4,530
Grants receivable from the chief scientist	73,050	58,412
T o t a l current assets	23,686,895	8,644,276
LONG TERM DEPOSITS AND INVESTMENT	4,593	4,593
AMOUNTS FUNDED IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT	6,304	5,545
PROPERTY AND EQUIPMENT, NET	12,164	5,768
T o t a l assets	23,709,956	8,660,182
CURRENT LIABILITIES:
Accounts payable and accrued expenses	302,567	450,941
Account payable with former shareholder	47,252	47,252
T o t a l current liabilities	349,819	498,193
LONG TERM LIABILITIES:
Employee rights upon retirement	9,212	8,004
Provision for uncertain tax position	23,210	23,210
Total long term liabilities	32,422	31,214
COMMITMENTS (note 2)
STOCKHOLDERS' EQUITY:
Common stock, $ 0.012 par value (16,666,667 authorized shares; 9,776,167 and 7,937,872 shares issued and outstanding as of February 28, 2014 and August 31, 2013, respectively)	117,298	95,238
Additional paid-in capital	46,726,183	29,855,723
Accumulated other comprehensive income	846,985	303,403
Deficit accumulated during the development stage	(24,362,751)	(22,123,589)
T o t a l stockholders' equity	23,327,715	8,130,775
T o t a l liabilities and stockholders' equity	$ 23,709,956	$ 8,660,182

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - $ / shares	Feb. 28, 2014	Aug. 31, 2013
CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]
Common stock, par value per share	$ 0.012	$ 0.012
Common stock, shares authorized	16,666,667	16,666,667
Common stock, shares issued	9,776,167	7,937,872
Common stock, shares outstanding	9,776,167	7,937,872

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended		143 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract]
RESEARCH AND DEVELOPMENT EXPENSES, net	$ 673,334	$ 748,996	$ 1,423,844	$ 1,141,622	$ 13,228,332
IMPAIRMENT OF INVESTMENT					434,876
GENERAL AND ADMINISTRATIVE EXPENSES	512,252	510,834	929,979	850,047	11,123,655
OPERATING LOSS	1,185,586	1,259,830	2,353,823	1,991,669	24,786,863
FINANCIAL INCOME	(73,957)	(66,800)	(120,080)	(139,044)	(507,733)
FINANCIAL EXPENSES	3,213	32,844	5,419	332,002	699,245
GAIN ON SALE OF INVESTMENT					(1,033,004)
IMPAIRMENT OF AVAILABLE-FOR-SALE SECURITIES					381,666
LOSS BEFORE TAXES ON INCOME	1,114,842	1,225,874	2,239,162	2,184,627	24,327,037
TAXES ON INCOME					35,714
NET LOSS FOR THE PERIOD	1,114,842	1,225,874	2,239,162	2,184,627	24,362,751
SUBSEQUENT INCREASE IN THE FAIR VALUE OF AVAILABLE FOR SALE SECURITIES PREVIOUSLY WRITTEN DOWN AS IMPAIRED	(48,498)	(5,630)	(53,820)	(122,977)	(184,665)
RECLASSIFICATION ADJUSTMENT FOR GAINS INCLUDED IN NET LOSS	25,937	50,687	44,391	50,687	134,761
UNREALIZED GAIN ON AVAILABLE FOR SALE SECURITIES	(490,251)	(53,697)	(534,153)	(172,218)	(797,081)
TOTAL OTHER COMPREHENSIVE INCOME	(512,812)	(8,640)	(543,582)	(244,508)	(846,985)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	$ 602,030	$ 1,217,234	$ 1,695,580	$ 1,940,119	$ 23,515,766
BASIC AND DILUTED LOSS PER COMMON SHARE	$ (0.12)	$ (0.17)	$ (0.26)	$ (0.31)
WEIGHTED AVERAGE NUMBER OF COMMON STOCK USED IN COMPUTING BASIC AND DILUTED LOSS PER COMMON STOCK	9,127,799	7,212,767	8,531,150	7,018,766

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock [Member]	Additional paid-in capital [Member]	Other Comprehensive Income [Member]	Deficit accumulated during the development stage [Member]
BALANCE at Apr. 11, 2002	$ 53,700	$ 34,828	$ 18,872
BALANCE, shares at Apr. 11, 2002		2,902,589
SHARES CANCELLED		$ (19,800)	19,800
SHARES CANCELLED, shares		(1,650,000)
SHARES ISSUED FOR INVESTMENT IN ISTI-NJ	434,876	$ 1,144	433,732
SHARES ISSUED FOR INVESTMENT IN ISTI-NJ, shares		95,368
SHARES ISSUED FOR OFFERING COSTS		$ 1,753	(1,753)
SHARES ISSUED FOR OFFERING COSTS, shares		146,079
SHARES AND WARRANTS ISSUED FOR CASH, NET	2,122,981	$ 27,181	2,095,800
SHARES AND WARRANTS ISSUED FOR CASH, NET, shares		2,265,514
SHARES ISSUED FOR CASH, NET	98,750
SHARES ISSUED FOR SERVICES RENDERED		$ 125	98,625
SHARES ISSUED FOR SERVICES RENDERED, shares		10,417
CONTRIBUTIONS TO PAID IN CAPITAL	18,991		18,991
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	1,968,547		1,968,547
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	177,782		177,782
DISCOUNT ON CONVERTIBLE NOTE RELATED TO BENEFICIAL CONVERSION FEATURE	108,000		108,000
OTHER COMPREHENSIVE INCOME (LOSS)	(16)				(16)
IMPUTED INTEREST	8,437		8,437
NET LOSS	(4,478,917)				(4,478,917)
BALANCE at Aug. 31, 2007	513,131	$ 45,231	4,946,833		(4,478,933)
BALANCE, shares at Aug. 31, 2007		3,769,967
BALANCE at Apr. 11, 2002	53,700	$ 34,828	18,872
BALANCE, shares at Apr. 11, 2002		2,902,589
OTHER COMPREHENSIVE INCOME (LOSS)	846,985
NET LOSS	(24,362,751)
BALANCE at Feb. 28, 2014	$ 23,327,715	$ 117,298	46,726,183	846,985	(24,362,751)
BALANCE, shares at Feb. 28, 2014	9,776,167	9,776,167
BALANCE at Aug. 31, 2007	$ 513,131	$ 45,231	4,946,833		(4,478,933)
BALANCE, shares at Aug. 31, 2007		3,769,967
SHARES AND WARRANTS ISSUED FOR CASH, NET	5,784,800	$ 10,178	5,774,622
SHARES AND WARRANTS ISSUED FOR CASH, NET, shares		848,288
SHARES ISSUED FOR SERVICES RENDERED	116,110	$ 293	115,817
SHARES ISSUED FOR SERVICES RENDERED, shares		24,419
RECEIPTS ON ACCOUNT OF SHARES AND WARRANTS	6,061		6,061
SHARES ISSUED FOR CONVERSION OF CONVERTIBLE NOTE	275,000	$ 550	274,450
SHARES ISSUED FOR CONVERSION OF CONVERTIBLE NOTE, shares		45,844
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	459,467		459,467
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	203,982		203,982
IMPUTED INTEREST	3,780		3,780
NET LOSS	(2,769,271)				(2,769,271)
BALANCE at Aug. 31, 2008	4,593,060	$ 56,252	11,785,012		(7,248,204)
BALANCE, shares at Aug. 31, 2008		4,688,518
SHARES ISSUED FOR SERVICES RENDERED	152,928	$ 204	152,724
SHARES ISSUED FOR SERVICES RENDERED, shares		17,012
SHARES TO BE ISSUED FOR SERVICES RENDERED	203,699		203,699
SHARES TO BE ISSUED FOR SERVICES RENDERED, shares
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	436,025		436,025
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	117,174		117,174
IMPUTED INTEREST	3,780		3,780
NET LOSS	(2,760,474)				(2,760,474)
BALANCE at Aug. 31, 2009	2,746,192	$ 56,456	12,698,414		(10,008,678)
BALANCE, shares at Aug. 31, 2009		4,705,530
SHARES ISSUED FOR SERVICES RENDERED	249,850	$ 1,109	248,741
SHARES ISSUED FOR SERVICES RENDERED, shares		92,416
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	690,882		690,882
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	116,944		116,944
IMPUTED INTEREST	3,780		3,780
NET LOSS	(2,977,376)				(2,977,376)
BALANCE at Aug. 31, 2010	830,272	$ 57,565	13,758,761		(12,986,054)
BALANCE, shares at Aug. 31, 2010		4,797,946
SHARES AND WARRANTS ISSUED FOR CASH, NET	3,694,212	$ 11,808	3,682,404
SHARES AND WARRANTS ISSUED FOR CASH, NET, shares		984,209
SHARES ISSUED FOR SERVICES RENDERED	227,569	$ 731	226,838
SHARES ISSUED FOR SERVICES RENDERED, shares		60,887
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	502,593		502,593
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	26,733		26,733
IMPUTED INTEREST	3,782		3,782
NET LOSS	(1,561,245)				(1,561,245)
BALANCE at Aug. 31, 2011	3,723,916	$ 70,104	18,201,111		(14,547,299)
BALANCE, shares at Aug. 31, 2011		5,843,042
SHARES AND WARRANTS ISSUED FOR CASH, NET	2,944,464	$ 9,622	2,984,842
SHARES AND WARRANTS ISSUED FOR CASH, NET, shares		801,942
SHARES AND/OR WARRANTS TO BE ISSUED	25,093		25,093
SHARES ISSUED FOR SERVICES RENDERED	107,860	$ 349	107,511
SHARES ISSUED FOR SERVICES RENDERED, shares		29,084
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	200,866		200,866
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	70,292		70,292
NET LOSS	(3,344,478)				(3,344,478)
BALANCE at Aug. 31, 2012	3,778,013	$ 80,075	21,589,715		(17,891,777)
BALANCE, shares at Aug. 31, 2012		6,674,068
SHARES AND WARRANTS ISSUED FOR CASH, NET	1,422,592	$ 4,192	1,418,400
SHARES AND WARRANTS ISSUED FOR CASH, NET, shares		349,396
SHARES ISSUED FOR CASH, NET	4,238,889	$ 7,897	4,230,992
SHARES ISSUED FOR CASH, NET, shares		658,144
SHARES ISSUED FOR SERVICES RENDERED	244,457	$ 404	224,053
SHARES ISSUED FOR SERVICES RENDERED, shares		33,709
SHARES ISSUED FOR MARKETABLE SECURITIES	628,630	$ 2,390	626,240
SHARES ISSUED FOR MARKETABLE SECURITIES, shares		199,172
EXCHANGE OF WARRANTS (see note 5)	917,809		917,809
EXERCISE OF WARRANTS AND OPTIONS	109,575	$ 280	109,295
EXERCISE OF WARRANTS AND OPTIONS, shares		23,383
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	562,966		562,966
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	156,253		156,253
OTHER COMPREHENSIVE INCOME (LOSS)	303,403			303,403
NET LOSS	(4,231,812)				(4,231,812)
BALANCE at Aug. 31, 2013	$ 8,130,775	$ 95,238	29,855,723	303,403	(22,123,589)
BALANCE, shares at Aug. 31, 2013	7,937,872	7,937,872
SHARES ISSUED FOR CASH, NET	$ 14,887,085	$ 18,960	14,868,125
SHARES ISSUED FOR CASH, NET, shares	1,580,000	1,580,000
SHARES AND/OR WARRANTS TO BE ISSUED	$ 118,128		118,128
SHARES ISSUED FOR SERVICES RENDERED	64,400	$ 120	64,280
SHARES ISSUED FOR SERVICES RENDERED, shares		10,000
EXERCISE OF WARRANTS AND OPTIONS	1,489,770	$ 2,980	1,486,790
EXERCISE OF WARRANTS AND OPTIONS, shares		248,295
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	276,121		276,121
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	57,016		57,016
OTHER COMPREHENSIVE INCOME (LOSS)	543,582			543,582
NET LOSS	(2,239,162)				(2,139,162)
BALANCE at Feb. 28, 2014	$ 23,327,715	$ 117,298	$ 46,726,183	$ 846,985	$ (24,362,751)
BALANCE, shares at Feb. 28, 2014	9,776,167	9,776,167

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)	12 Months Ended
	Aug. 31, 2011 shares
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY [Abstract]
Shares issued for finders' fee	13,872

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended		143 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,239,162)	$ (2,184,627)	$ (24,362,751)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	2,983	2,899	129,206
Amortization of debt discount			108,000
Exchange differences on deposits and investments	(33,426)	25,039	16,790
Stock based compensation	333,137	441,084	6,023,643
Shares issued for services rendered	64,400		1,464,813
Gain on sale of investment	(44,391)	(28,034)	(1,128,098)
Impairment of investment			434,876
Imputed interest			23,559
Impairment of available for sales security			381,666
Exchange of warrants		296,982	296,982
Changes in fair value of warrant liabilities		(44,699)	98,005
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(167,313)	(403,870)	(330,566)
Restricted cash			(16,000)
Accounts payable and accrued expenses	(148,374)	(175,031)	302,567
Liability of employee rights upon retirement	1,208	4,667	22,439
Provision for uncertain tax position			23,210
Total net cash used in operating activities	(2,230,938)	(2,065,590)	(16,511,659)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(9,379)		(141,370)
Acquisition of short-term investments and short-term deposits	(18,600,000)	(1,862,817)	(30,350,363)
Funds in respect of employee rights upon retirement	(500)	(1,331)	(9,485)
Proceeds from sale of investment and marketable securities	80,249	114,130	756,920
Proceeds from sale of short-term deposits	5,236,286		11,718,297
Lease deposits, net			(2,615)
Total net cash derived from (used in) investing activities	(13,293,344)	(1,750,018)	(18,028,616)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants - net of issuance expenses	14,887,085	1,450,936	35,746,638
Proceeds from exercise of warrants and options	1,489,770		1,599,345
Proceeds from shares to be issued for exercise of warrants	118,128		118,128
Receipts on account of shares issuances			6,061
Proceeds from convertible notes			275,000
Proceeds from short term note payable			120,000
Payments of short term note payable			(120,000)
Shareholder advances			66,243
Net cash provided by financing activities	16,494,983	1,450,936	37,811,415
EFFECT OF EXCHANGE RATE CHANGES ON CASH	9,982	(26,163)	(18,229)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	980,683	(2,390,835)	3,252,911
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	2,272,228	4,430,740
CASH AND CASH EQUIVALENTS AT END OF PERIOD	3,252,911	2,039,905	3,252,911
Non cash investing and financing activities:
Shares issued for offering costs			77,779
Contribution to paid in capital			18,991
Discount on convertible note related to beneficial conversion feature			108,000
Exchange of warrants		917,809	917,809
Shares and warrants issued for marketable securities		$ 628,630	$ 628,630

SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Feb. 28, 2014

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:

General:

Incorporation and operations

Oramed Pharmaceuticals Inc. (the "Company") was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd ("Hadasit") to acquire the provisional patent related to an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes. In subsequent periods, the Company entered into additional development agreements with Hadasit, the most recent of which was signed on September 11, 2011. See also note 2a.

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term "Group" refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd. (the "Subsidiary").

Development and liquidity risks

The Company has been in the development stage since its formation and has not yet generated any revenues from its operations. Continued operation of the Company is contingent upon obtaining sufficient funding until it becomes profitable.

The Group is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with ASC Topic 915 "Development Stage Entities", due to the fact that it has not generated any revenues from its operations.

Successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the FDA prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.

Newly issued and recently adopted Accounting Pronouncements

In February 2013, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income ("ASU 2013-02"). This update requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, ASU 2013-02 requires presentation, either on the face of the income statement or in the notes, of significant amounts reclassified out of accumulated other comprehensive income by respective line items of net income, but only if the amounts reclassified are required to be reclassified in their entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about these amounts. The amendments in ASU 2013-02 will be effective prospectively for annual reporting periods beginning after December 15, 2012, and interim periods within those annual periods. The Company adopted ASU 2013-02 in the first quarter of fiscal year 2014. The adoption of ASU 2013-02 did not have any material effect on the consolidated financial statement presentation.

Condensed Consolidated Financial Statements Preparation

The condensed consolidated financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and on the same basis as the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended August 31, 2013 (the "2013 Form 10-K"). These condensed consolidated financial statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair statement of the results of the periods presented. Certain information and disclosures normally included in annual consolidated financial statements have been omitted in this interim period report pursuant to the rules and regulations of the Securities and Exchange Commission. Because the condensed consolidated interim financial statements do not include all of the information and disclosures required by U.S. GAAP for annual financial statements, they should be read in conjunction with the audited consolidated financial statements and notes included in the 2013 Form 10-K. The results for interim periods are not necessarily indicative of a full fiscal year's results.

COMMITMENTS

6 Months Ended

Feb. 28, 2014

COMMITMENTS [Abstract]

COMMITMENTS

NOTE 2 - COMMITMENTS:

On September 11, 2011, the Subsidiary entered into an agreement with Hadasit, Dr. Miriam Kidron and Dr. Daniel Schurr (the "Agreement"), to retain consulting and clinical trial services. According to the Agreement, Hadasit will be entitled to a consideration of $200,000 to be paid by the Company in accordance with the actual progress of the studies, $75,000 of which were paid and recognized through February 28, 2014. See also note 1a(1).

On July 5, 2010, the Subsidiary of the Company entered into a Manufacturing Supply Agreement ("MSA") with Sanofi-Aventis Deutschland GMBH ("Sanofi"). According to the MSA, Sanofi will supply the Subsidiary with specified quantities of recombinant human insulin to be used for clinical trials in the United States.

On February 15, 2011, the Subsidiary entered into a consulting agreement with a third party (the "Consultant") for a period of five years, pursuant to which the Consultant will provide consultation on scientific and clinical matters. The Consultant is entitled to a fixed monthly fee of $8,000, royalties of 8% of the net royalties actually received by the Subsidiary in respect of the patent that was sold to Entera Bio Ltd ("Entera") on March 31, 2011 and an option to purchase up to 20,834 shares of the Company at an exercise price of $6.00 per share. The option vests in five annual installments commencing February 16, 2012 and expires on February 16, 2021. The initial fair value of the option on the date of grant was $62,185, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 78.65%; risk-free interest rates of 3.62%; and the remaining expected term of 10 years. The fair value of the option as of February 28, 2014 was $197,332, using the following assumptions: dividend yield of 0% and expected term of 6.97 years; expected volatility of 81.58%; and risk-free interest rate of 2.13%. The fair value of the unvested options is remeasured at each balance sheet reporting date and is recognized over the related service period using the straight-line method.

On March 18, 2012, the Subsidiary entered into a lease agreement for its facilities in Israel. The lease agreement was for a period of 57 months commencing January 1, 2012.

On April 28, 2013, the Subsidiary entered into a new lease agreement for its office facilities in Israel, which replaced the lease agreement from 2012. The new lease agreement is for a period of 36 months commencing November 4, 2013. The annual lease payment will be NIS 89,052 from 2014 through 2016, and will be linked to the increase in the Israeli consumer price index ("CPI") (as of February 28, 2014, the future annual lease payments under the new agreement will be $25,422, based on the exchange rate as of February 28, 2014).

The lease expenses for the six and three month periods ended February 28, 2014 were approximately $9,603 and $5,715, respectively.

As security for its obligation under this lease agreement the Company provided a bank guarantee in an amount equal to three monthly lease payments.

On April 15, 2013, the Company entered into a consulting agreement with a third party advisor for a period of twelve months, pursuant to which such advisor will provide investor relations services and will be entitled to receive a monthly cash fee and 15,000 shares of the Company's common stock issued in three equal installments, on each of May 1, 2013, August 1, 2013 and November 15, 2013. On July 11 and November 4, 2013 the Company issued to such advisor 5,000 and 10,000 shares, respectively. The fair value of the shares at these dates was $34,900 and $64,400, respectively. See also note 5.

On April 29, 2013, the Subsidiary entered into a Clinical Research Organization Service Agreement with a third party, to retain it as a Clinical Research Organization ("CRO"), for its Phase 2a clinical trial for an oral insulin capsule for type 2 diabetes patients. As consideration for its services, the Subsidiary will pay the CRO a total amount of approximately $332,702 that will be paid during the term of the engagement and based on achievement of certain milestones, $282,807 of which were paid and recognized through February 28, 2014.

On February 6, 2014, the Subsidiary entered into an additional agreement with the same CRO, to retain it as a CRO, for its Phase 2a clinical trial for an oral insulin capsule for type 1 diabetes patients, which is expected to be completed in approximately nine months. As consideration for its services, the Subsidiary will pay the CRO a total amount of approximately $280,008 that will be paid during the term of the engagement and based on achievement of certain milestones, none of which were paid or recognized through February 28, 2014.

On July 23, 2013, the Subsidiary entered into a Master Service Agreement with a vendor for the process development and production of one of its oral capsule ingredients in the amount of $102,280, of which $30,684 were paid and recognized through February 28, 2014.

Grants from Bio-Jerusalem

The Subsidiary is committed to pay royalties to the Bio-Jerusalem fund on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received by the Company (Israeli CPI linked) at the total amount of $65,053. As of February 28, 2014, the Subsidiary had not yet realized any revenues and did not incur any royalty liability.

During the six and three month period ended February 28, 2014, the Company received no grants from the Bio-Jerusalem fund. For the period from inception on April 12, 2002 through February 28, 2014, the research and development expenses are presented net of Bio-Jerusalem grants, in the total amount of $65,053.

Grants from the Office of the Chief Scientist of the Ministry of Economy (formerly the Ministry of Industry, Trade and Labor) of Israel ("OCS")

Under the terms of the Company's funding from the Israeli Government, royalties of 3%-3.5% are payable on sales of products developed from a project so funded, up to 100% of the amount of the grant received by the Company (dollar linked) with the addition of annual interest at a rate based on LIBOR

At the time the grants were received, successful development of the related projects was not assured. In case of failure of a project that was partly financed as above, the Company is not obligated to pay any such royalties.

On February 28, 2014, the Subsidiary had not yet realized any revenues from the said project and did not incur any royalty liability. The total amount that was actually received through February 28, 2014 is $1,783,994.

For the six and three month periods ended February 28, 2014, the research and development expenses are presented net of OCS and Bio-Jerusalem fund grants, in the total amount of $139,441 and $72,984, respectively.

FAIR VALUE

6 Months Ended

Feb. 28, 2014

FAIR VALUE [Abstract]

FAIR VALUE

NOTE 3 - FAIR VALUE:

Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:

Level 1:

Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2:

Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3:

Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

As of February 28, 2014 and August 31, 2013 the assets or liabilities measured at fair value were comprised of available for sale securities (level 1). See also note 4.

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.

As of February 28, 2014, the carrying amount of cash and cash equivalents, short term deposits, accounts receivable, other current assets and accounts payables and accrued expenses approximates their fair values due to the short-term maturities of these instruments.

The fair value of long-term deposits also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.

In order to secure the fulfillment of the Company's obligations under credit cards, the Company has placed a restricted deposit with the bank in an amount of $16,000.

The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost, and the Company's ability and intent to hold the investment. Realized gains and losses on sales of the securities are included in the consolidated statement of operations as financial income or expenses.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

MARKETABLE SECURITIES

6 Months Ended

Feb. 28, 2014

MARKETABLE SECURITIES [Abstract]

MARKETABLE SECURITIES

NOTE 4 - MARKETABLE SECURITIES:

As of February 28, 2014, marketable securities consisted wholly of equity securities of D.N.A Biomedical Solutions Ltd ("D.N.A").

During the six months ended February 28, 2014, the Subsidiary sold in aggregate 1,625,989 of the D.N.A shares for a total of $80,249.

As of February 28, 2014, the Group owns approximately 10.3% of D.N.A's outstanding ordinary shares.

The cost of the securities sold and the amount reclassified out of accumulated other comprehensive income into financial income (amounting to $44,391 during the six month period ended February 28, 2014), were determined by specific identification.

The D.N.A. shares are traded on the Tel Aviv Stock Exchange and have a quoted price. The fair value of those securities is measured at the quoted prices of the securities on the measurement date.

As of February 28, 2014 and August 31, 2013, the available for sale securities are classified as level 1 as described in the table below:

	Level 1
Marketable securities:
February 28, 2014	$	1,464,100
August 31, 2013	$	956,376

Available-for-sale securities are reported at fair value, with unrealized gains and losses recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

STOCK HOLDERS' EQUITY

6 Months Ended

Feb. 28, 2014

STOCK HOLDERS' EQUITY [Abstract]

STOCK HOLDERS' EQUITY

NOTE 5 - STOCK HOLDERS' EQUITY:

As described in note 2e, on November 4, 2013, the Company issued 10,000 shares of its common stock to an advisor as remuneration for services rendered. The total fair value of the shares at the date of grant was $64,400.

On December 24, 2013, the Company entered into a Placement Agency Agreement with Aegis Capital Corp. (the "Placement Agent"), pursuant to which the Placement Agent agreed to use its reasonable best efforts to arrange for the sale of up to 1,580,000 shares of the Company's common stock. In connection therewith, on December 24, 2013, the Company entered into a Securities Purchase Agreement, pursuant to which the Company agreed to sell an aggregate of 1,580,000 shares of common stock, at a price of $10.00 per share, to two institutional investors in a registered direct offering (the "Offering"). The Company received all funds and issued all shares of common stock in connection with the Offering as of December 30, 2013. The net proceeds to the Company from the Offering were approximately $14,887,085, after deducting Placement Agent's commissions of $815,500 and other offering expenses of the Company.

During January 2014, 258,849 warrants were exercised for cash and resulted in the issuance of 239,161 shares of common stock. Additional 19,688 shares were issued in April 2014. The cash consideration received for the exercise of the warrants was $1,553,094.

During January and February 2014, 9,134 options were exercised as part of the Company's stock based compensation plan for cash and resulted in the issuance of 9,134 shares of common stock.

The cash consideration received for exercise of the options was $54,804.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

SUBSEQUENT EVENTS

6 Months Ended

Feb. 28, 2014

SUBSEQUENT EVENTS [Abstract]

SUBSEQUENT EVENTS

NOTE 6 - SUBSEQUENT EVENTS

During March 2014, the Subsidiary sold in aggregate 1,000,000 of the D.N.A shares for a total of $57,340. As of April 8, 2014, the Group owns approximately 9.8% of D.N.A's outstanding ordinary shares.

During March 2014, 9,434 options were exercised as part of the Company's stock based compensation plan for cash and resulted in the issuance of 9,434 shares of common stock.

The cash consideration received for exercise of the options was $48,739.

During April 2014, 137,300 warrants were exercised for cash and resulted in the issuance of 137,300 shares of common stock. The cash consideration received for exercise of warrants was $1,648.

SIGNIFICANT ACCOUNTING POLICIES (Policy)

6 Months Ended

Feb. 28, 2014

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

General

General:

Incorporation and operations

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

Development and liquidity risks

Newly issued and recently adopted Accounting Pronouncements

Condensed Consolidated Financial Statements Preparation

MARKETABLE SECURITIES (Tables)

6 Months Ended

Feb. 28, 2014

MARKETABLE SECURITIES [Abstract]

Schedule of Marketable Securities

	Level 1
Marketable securities:
February 28, 2014	$	1,464,100
August 31, 2013	$	956,376

SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Details)	Aug. 31, 2013 shares	Aug. 31, 2011 USD ($) shares	Feb. 28, 2014 shares	Jan. 10, 2013 shares
SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Cost method investment \| $		$ 1,027
Note receivable, interest rate		0.45%
Note receivable, principal amount \| $		$ 450,000
Number of D.N.A. shares owned		8,404,667
Royalty receivable percentage			3.00%
Reverse stock split ratio	12
Common stock, shares issued prior to reverse stock split				86,500,000
Common stock, shares outstanding prior to reverse stock split				86,500,000
Common stock, shares authorized prior to reverse stock split				200,000,000
Common stock, shares issued	7,937,872		9,776,167	7,200,000
Common stock, shares outstanding	7,937,872		9,776,167	7,200,000
Common stock, shares authorized	16,666,667		16,666,667

COMMITMENTS (Service Agreements) (Details) - USD ($)	6 Months Ended		12 Months Ended		143 Months Ended
COMMITMENTS (Service Agreements) (Details) - USD ($)	Feb. 28, 2014	Feb. 28, 2013	Aug. 31, 2013	Aug. 31, 2011	Feb. 28, 2014
Long-term Purchase Commitment [Line Items]
Shares issued for services	10,000
Shares issued for services rendered	$ 64,400				$ 1,464,813
Hadasit [Member]
Long-term Purchase Commitment [Line Items]
Commitments for consulting services					200,000
Consulting services					75,000
Consultant [Member]
Long-term Purchase Commitment [Line Items]
Agreement term				5 years
Commitments for consulting service, monthly fixed fee	$ 8,000				$ 8,000
Royalty percentage	8.00%				8.00%
Options granted				20,834
Options granted, exercise price				$ 6.00
Vesting period				5 years
Capitalized cost	$ 197,332			$ 62,185
Dividend yield	0.00%			0.00%
Expected volatility	81.58%			78.65%
Risk-free interest rate	2.13%			3.62%
Expected term	6 years 11 months 19 days			10 years
Advisor [Member]
Long-term Purchase Commitment [Line Items]
Agreement term			12 months
Shares authorized for issuance for services			15,000
Shares issued for services	10,000		5,000
Shares issued for services rendered	$ 64,400		$ 34,900
Clinical Research Organization Service Agreement [Member]
Long-term Purchase Commitment [Line Items]
Commitments for consulting services	$ 280,008		332,702
Consulting services					$ 282,807
Master Service Agreement [Member]
Long-term Purchase Commitment [Line Items]
Commitments for consulting services			$ 102,280		$ 30,684

COMMITMENTS (Leases) (Details)	3 Months Ended	6 Months Ended	12 Months Ended
COMMITMENTS (Leases) (Details)	Feb. 28, 2014 USD ($)	Feb. 28, 2014 USD ($)	Aug. 31, 2012	Feb. 28, 2014 ILS (₪)
COMMITMENTS [Abstract]
Operating lease term		36 months	57 months
Annual lease payments:
2014	$ 25,422	$ 25,422		₪ 89,052
2015	25,422	25,422		89,052
2016	25,422	25,422		₪ 89,052
Lease expense	$ 5,715	$ 9,603

COMMITMENTS (Research Grants) (Details)	3 Months Ended	6 Months Ended	143 Months Ended
COMMITMENTS (Research Grants) (Details)	Feb. 28, 2014 USD ($)	Feb. 28, 2014 USD ($)	Feb. 28, 2014 USD ($)
Bio-Jerusalem [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty percentage	4.00%	4.00%	4.00%
Royalty percentage, maximum percentage of grants received	100.00%	100.00%	100.00%
Royalty liability	$ 0	$ 0	$ 0
Grants receivable	65,053	65,053	65,053
Grants received	$ 0	$ 0	$ 65,053
Chief Scientist Office [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty percentage, maximum percentage of grants received	100.00%	100.00%	100.00%
Royalty liability	$ 0	$ 0	$ 0
Grants received	$ 72,984	$ 139,441	$ 1,783,994
Chief Scientist Office [Member] \| Minimum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty percentage	3.00%	3.00%	3.00%
Chief Scientist Office [Member] \| Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty percentage	3.50%	3.50%	3.50%

FAIR VALUE (Details)	Feb. 28, 2014 USD ($)
FAIR VALUE [Abstract]
Restricted deposit	$ 16,000

MARKETABLE SECURITIES (Details) - USD ($)	3 Months Ended		6 Months Ended		143 Months Ended
MARKETABLE SECURITIES (Details) - USD ($)	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Aug. 31, 2013
MARKETABLE SECURITIES [Abstract]
Number of shares sold			1,625,989
Proceeds from sale of marketable securities			$ 80,249
Ownership percentage	10.30%		10.30%		10.30%
Amount reclassified to earnings	$ 25,937	$ 50,687	$ 44,391	$ 50,687	$ 134,761
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	$ 1,464,100		$ 1,464,100		$ 1,464,100	$ 956,376

STOCK HOLDERS' EQUITY (Details) - USD ($)	1 Months Ended	6 Months Ended		143 Months Ended
STOCK HOLDERS' EQUITY (Details) - USD ($)	Apr. 08, 2014	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014
STOCK HOLDERS' EQUITY [Abstract]
Shares issued for services		10,000
Value of shares issued for services		$ 64,400		$ 1,464,813
Shares issued for cash		1,580,000
Shares issued for cash, price per share		$ 10.00
Proceeds from issuance of common stock		$ 14,887,085
Stock issuance costs including commisions		$ 815,500
Number of warrants exercised		258,849
Shares issued for warrants exercised	19,688	239,161
Proceeds from exercise of warrants		$ 1,553,094
Shares issued for stock options exercised		9,134
Proceeds from exercise of stock options		$ 54,804

SUBSEQUENT EVENTS (Details) - USD ($)	1 Months Ended	6 Months Ended
SUBSEQUENT EVENTS (Details) - USD ($)	Apr. 08, 2014	Feb. 28, 2014
Subsequent Event [Line Items]
Ownership percentage		10.30%
Proceeds from sale of marketable securities		$ 80,249
Number of shares sold		1,625,989
Shares issued for stock options exercised		9,134
Proceeds from exercise of stock options		$ 54,804
Shares issued for warrants exercised	19,688	239,161
Proceeds from exercise of warrants		$ 1,553,094
Subsequent Event [Member]
Subsequent Event [Line Items]
Ownership percentage	9.80%
Proceeds from sale of marketable securities	$ 57,340
Number of shares sold	1,000,000
Shares issued for stock options exercised	9,434
Proceeds from exercise of stock options	$ 48,739
Shares issued for warrants exercised	137,300
Proceeds from exercise of warrants	$ 1,648